December 8, 2021
In December 2021, AliveX Co-founder & Chief Strategy Officer Dr. Dimitirs Chritodoulou was interviewed by Pharma Tech Outlook Magazine on how AliveX, as an emerging star in immunotherapy, innovates the drug discovery R&D process by decoding the human immune system and identifying novel biomarkers and therapeutic targets for more targeted and precision medicine.
"We are here because we want to change the paradigm of how life science research is done. We want to move away from the limited single-molecule-oriented view and focus on a systems-view that can significantly improve the efficiency of R&D. We target the immune system, which we believe is one of the fundamental pillars of the present and future of life sciences," adds Dr. Christodoulou. AliveX generates and combines multi-omics data, with computational biology and machine learning, to decode the human immune system and identify new biomarkers and therapeutic targets in oncology and auto-immune diseases, with higher precision and success probability.
AliveX offers a namesake end-to-end, integrated, AI immunology platform for advanced biomarker discovery and target identification. By combining and integrating different types of omics information ranging from transcriptomics, metabolomics, fluxomics, and proteomics through its multi-omics platform, AliveX empowers the systemic understanding of the human immune system. It transforms the expansive and complex multi-omics data that it generates into knowledge and insights through its proprietary knowledge graph, data intelligence, (explainable) AI and computational modelling pipelines to ultimately reach a deep, mechanistic understanding of complex phenomena and uncover the “invisible” mechanisms governing them. This enables more targeted and precise treatment development with higher probability of clinical success, while saving the industry billions of dollars in unsuccessful R&D efforts.
To read the full interview article, please visit - Pharma Tech Outlook